Switch to: Citations

Add references

You must login to add references.
  1. Understanding Pharmaceutical Research Manipulation in the Context of Accounting Manipulation.Abigail Brown - 2013 - Journal of Law, Medicine and Ethics 41 (3):611-619.
    Good decision-making requires reliable information. In medicine, relevant information comes from clinical trials and other forms of scientific research. In business, one source is in corporate annual financial statements. As for-profit, publicly traded companies whose business is discovering, manufacturing, and marketing drugs, pharmaceutical companies sit at the nexus of these two fields. Determining the safety and efficacy of a pharmaceutical product and determining the profitability of a complex enterprise are similarly difficult tasks: each is fraught with deeply ambiguous information that (...)
    Download  
     
    Export citation  
     
    Bookmark   10 citations  
  • Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs.Donald W. Light, Joel Lexchin & Jonathan J. Darrow - 2013 - Journal of Law, Medicine and Ethics 41 (3):590-600.
    Institutional corruption is a normative concept of growing importance that embodies the systemic dependencies and informal practices that distort an institution’s societal mission. An extensive range of studies and lawsuits already documents strategies by which pharmaceutical companies hide, ignore, or misrepresent evidence about new drugs; distort the medical literature; and misrepresent products to prescribing physicians. We focus on the consequences for patients: millions of adverse reactions. After defining institutional corruption, we focus on evidence that it lies behind the epidemic of (...)
    Download  
     
    Export citation  
     
    Bookmark   22 citations  
  • Key Opinion Leaders and the Corruption of Medical Knowledge: What the Sunshine Act Will and Won’t Cast Light on.Sergio Sismondo - 2013 - Journal of Law, Medicine and Ethics 41 (3):635-643.
    The pharmaceutical industry, in its marketing efforts, often turns to “key opinion leaders” or “KOLs” to disseminate scientific information. Drawing on the author's fieldwork, this article documents and examines the use of KOLs in pharmaceutical companies’ marketing efforts. Partly due to the use of KOLs, a small number of companies with well-defined and narrow interests have inordinate influence over how medical knowledge is produced, circulated, and consumed. The issue here, as in many other cases of institutional corruption, is that a (...)
    Download  
     
    Export citation  
     
    Bookmark   23 citations  
  • The influence of ethical fit on employee satisfaction, commitment and turnover.Randi L. Sims & K. Galen Kroeck - 1994 - Journal of Business Ethics 13 (12):939 - 947.
    This study examines the influence of ethical fit on employee attitudes and intentions to turnover. The results of this investigation provides support for the conjecture that ethical work climate is an important variable in the study of person-organization fit. Ethical fit was found to be significantly related to turnover intentions, continuance commitment, and affective commitment, but not to job satisfaction. Results are discussed in regard to some of the affective and cognitive distinctions among satisfaction, commitment, and behavioral intentions.
    Download  
     
    Export citation  
     
    Bookmark   50 citations  
  • (1 other version)Global health impact: A basis for labeling and licensing campaigns?Nicole Hassoun - 2012 - Developing World Bioethics 12 (3):121-134.
    Most of the world's health problems afflict poor countries and their poorest inhabitants. There are many reasons why so many people die of poverty-related causes. One reason is that the poor cannot access many of the existing drugs and technologies they need. Another, is that little of the research and development (R&D) done on new drugs and technologies benefits the poor. There are several proposals on the table that might incentivize pharmaceutical companies to extend access to essential drugs and technologies (...)
    Download  
     
    Export citation  
     
    Bookmark   8 citations  
  • (1 other version)Measuring Global Health Impact: Incentivizing Research and Development of Drugs for Neglected Diseases.Nicole Hassoun - 2012 - Developing World Bioethics 12 (3):121-134.
    ABSTRACT Most of the world's health problems afflict poor countries and their poorest inhabitants. There are many reasons why so many people die of poverty‐related causes. One reason is that the poor cannot access many of the existing drugs and technologies they need. Another, is that little of the research and development (R&D) done on new drugs and technologies benefits the poor. There are several proposals on the table that might incentivize pharmaceutical companies to extend access to essential drugs and (...)
    Download  
     
    Export citation  
     
    Bookmark   7 citations  
  • Patents, biomedical research, and treatments: Examining concerns, canvassing solutions.Josephine Johnston & Angela A. Wasunna - 2007 - Hastings Center Report 37 (1):1-36.
    Download  
     
    Export citation  
     
    Bookmark   6 citations